Compare DuPont de Nemours Inc (DD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs GeneDx Holdings Corp — how do they compare? DuPont de Nemours Inc trades at $130.1 (market cap $17.89B), while GeneDx Holdings Corp trades at $67.59 (market cap $2.02B). The key difference: DuPont de Nemours Inc is far larger — about 8.9× GeneDx Holdings Corp's market cap, and DuPont de Nemours Inc pays a 1.81% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and GeneDx Holdings Corp for 19 Days on average.
| DD | WGS | |
|---|---|---|
Market Cap | $17.89B | $2.02B |
Volume | 816,409 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $167.51 |
52-Week Low | $92.49 | $34.51 |
Typical Hold Time | 89 Days | 19 Days |
Enterprise Value | $19.28B | $2.05B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $131.08, down 1.65% on the day, with a neutral technical signal and mixed fundamentals. Recent earnings have consistently beaten estimates, but 2025 saw a net loss of $779 million on revenue of $6.85 billion. The company maintains innovation with new product launches like the Sugar Separation Advisor and Tyvek with Renewable Attribution, while facing headwinds from legal settlements and uneven demand.
The outlook is cautious; analyst consensus is bullish with a 58.54% buy rating but a price target of $95.00 below the current price. Key opportunities include margin expansion in growth markets, while risks involve PFAS litigation costs, volatile cash flows, and execution challenges in a competitive landscape.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
